The global healthcare company Novo Nordisk is investing 134 million euros (close to 1 billion Danish kroner) in a new factory in Kalundborg, Denmark, for the production of biopharmaceuticals such as haemophilia medicine, growth hormone and other current and future pharmaceuticals.
The factory is expected to create 120–150 new jobs in Kalundborg over the next three years.
The plans for the new factory have been underway since June of last year and were finally approved last week. Groundbreaking for the new factory will take place on 22 August.
The new factory will cover formulation, freeze-drying, filling and packaging of a range of Novo Nordisk's biopharmaceuticals.
"We already have similar production in Gentofte, Denmark, and have built up great expertise in the production of biopharmaceuticals in Denmark. We were therefore never in doubt that this new factory should be placed in Denmark," said Per Valstorp in a press release sent out by Novo Nordisk yesterday
The large scale investment from Novo Nordisk underlines the fact that Denmark has one of the strongest clusters within life sciences in Europe, says Rasmus Beedholm-Ebsen, regional investment manager, Life Sciences, from Invest in Denmark.
- Denmark is a perfect base for activities within life sciences, especially when it comes to research and development and production. We have a strong position within the field where pharmaceutical companies are a part of a dense network also consisting of universities and hospitals. The Danish life sciences industry is an international example of how to turn academic knowledge into business, says Rasmus Beedholm-Ebsen.